Chronic inhibition of nuclear factor-kappaB attenuates renal injury in the 5/6 renal ablation model.
Recent studies indicated that the nuclear transcription factor, NF-kappaB, activates a number of proinflammatory genes in subjects with progressive nephropathies. We investigated whether NF-kappaB inhibition limits progressive renal injury in the 5/6 renal ablation model (Nx). Adult male Munich-Wistar rats were subdivided in four groups: S (n = 16), subjected to sham operation; S+PDTC (n = 18), sham-operated rats receiving the NF-kappaB inhibitor pyrrolidine-dithiocarbamate (PDTC; 60 mg x kg(-1) x day(-1)) in drinking water; Nx (n = 16), Nx rats receiving vehicle only; and Nx+PDTC (n = 19), Nx rats given PDTC as above. Thirty days after renal ablation, Nx rats exhibited systemic and glomerular hypertension. Only the former was attenuated by PDTC treatment. Sixty days after renal ablation, Nx rats exhibited marked hypertension, albuminuria and creatinine retention, as well as glomerulosclerosis and cortical interstitial expansion/inflammation. Immunohistochemical analysis of Nx rats showed renal interstitial infiltration by macrophages and by cells staining positively for ANG II and its receptor, AT(1). Glomerular and interstitial cells expressing the p65 subunit of the NF-kappaB system were also found. PDTC treatment attenuated renal injury and inflammation, as well as the density of cells staining positively for the p65 subunit. Activation of the NF-kappaB system plays an important role in the pathogenesis of renal injury in the Nx model. Inhibition of this system may represent a new strategy to prevent the progression of chronic kidney disease.
Fujihara
Clarice K
CK
Renal Division, Department of Clinical Medicine, Faculty of Medical Sciences, University of São Paulo, São Paulo, Brazil.
Antunes
Gláucia R
GR
Mattar
Ana L
AL
Malheiros
Denise M A C
DM
Vieira
José M
JM
Zatz
Roberto
R
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D007150:Immunohistochemistry; D007249:Inflammation / Q000473:pathology; D007668:Kidney / Q000473:pathology*; D007674:Kidney Diseases / Q000473:pathology / Q000517:prevention & control*; D008264:Macrophages / Q000502:physiology; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D009392:Nephrectomy; D009929:Organ Size / Q000502:physiology; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012079:Renal Circulation / Q000187:drug effects; D013859:Thiocarbamates / Q000494:pharmacology*; D051996:Transcription Factor RelA / Q000378:metabolism
D016328:NF-kappa B; D011759:Pyrrolidines; D013859:Thiocarbamates; D051996:Transcription Factor RelA; C020972:pyrrolidine dithiocarbamic acid